Merck Enters Research & Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) November 10, 2025
IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies November 10, 2025
Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies November 10, 2025
Dispatch Bio Announces Clinical Supply and Collaboration Agreement with BMS in Solid Tumors November 10, 2025
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors November 10, 2025
Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers published in eBioMedicine November 4, 2025
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development November 4, 2025
Myrio Therapeutics, University of Pennsylvania, and NYU Langone Health to develop next gen solid tumor T cell immunotherapeutics November 4, 2025
Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers November 4, 2025
SIOP 2025: Latest data of zurletrectinib (ICP-723) for the treatment of pediatric and adolescent patients with advanced solid tumors announced November 4, 2025
Updated Rezatapopt Monotherapy Interim Data Announced From PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation October 29, 2025
Takeda enters a license and collaboration agreement with Innovent Biologics for IBI363 and IBI343 October 29, 2025
FDA grants non-transferrable voucher for daraxonrasib (RMC-6236) under the Commissioner’s National Priority Voucher (CNPV) pilot program October 29, 2025
Preliminary Data from Ongoing Ph 1/2a Dose Escalation Trial of VS-7375 in Patients with KRAS G12D Mutant Solid Tumors Announced October 29, 2025
Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Announced October 29, 2025
Hansoh Pharma signs a licence agreement worth up to $1.45B with Roche for an investigational treatment of CRC and other solid tumours October 21, 2025
CTA Authorization and Initiation of Ph 0/1 Clinical Trial for TGW211 for the Treatment of HER2+ Tumors announced October 21, 2025
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors October 15, 2025
Positive feedback from MHRA provides alignment on the preclinical, manufacturing, clinical & regulatory pathway for ZI-MA4-1 and supports planned CTA submission October 15, 2025
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors October 8, 2025
